Christopher Chen
Stock Analyst at Robert W. Baird
(2.19)
# 3,223
Out of 5,119 analysts
6
Total ratings
40%
Success rate
7.9%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Christopher Chen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DFTX Definium Therapeutics | Reiterated: Buy | $57 → $79 | $33.27 | +137.45% | 3 | Sep 15, 2026 | |
| AMLX Amylyx Pharmaceuticals | Reiterated: Buy | $28 → $52 | $29.50 | +76.27% | 2 | Aug 18, 2026 | |
| LRMR Larimar Therapeutics | Reiterated: Buy | $5 | $2.39 | +109.21% | 1 | Jun 30, 2026 |
Definium Therapeutics
Sep 15, 2026
Reiterated: Buy
Price Target: $57 → $79
Current: $33.27
Upside: +137.45%
Amylyx Pharmaceuticals
Aug 18, 2026
Reiterated: Buy
Price Target: $28 → $52
Current: $29.50
Upside: +76.27%
Larimar Therapeutics
Jun 30, 2026
Reiterated: Buy
Price Target: $5
Current: $2.39
Upside: +109.21%